

Å

4

IPI VIRTUAL

Alternative Fund Event June 23 • 2pm-3:15pm ET

Connect with four experienced fund investors in Alt Credit, Bio + Tech, Climatetech and more. The event will identify managers that invest in ground breaking new founders helping to change the world and deliver innovative alternative strategies.

<u>Click here to register</u>

FUND: Chicago Atlantic Advisers - Alt Credit

ABOUT: An opportunistic credit-oriented investment firm seeking to capitalize on North American investment opportunities that are time-sensitive, complex, or in dislocated markets such as cannabis. The absence of traditional debt financing combined with the availability of high-quality retail and industrial real estate collateral makes our debt strategy one of the most attractive niches in the private credit space.

- Fund I, launched in 2019, has closed with over \$100mm in commitments
 19%+ annualized net fund return since inception.
- Fund II, launched in 2021, is raising \$200mm

FUND: E8 Ventures - Venture Capital, Seed and Series A, Climatetech

ABOUT: E8 Ventures will invest in early-stage climate technology companies, a sector poised for exceptional growth. The fund will build on the expertise, processes and track record of E8 Angels, a leading North American cleantech-focused private investor group, and on the positive results of the Element 8 Pilot Fund.

- E8 Ventures plans to make an estimated 15 early-stage investments in enabling technology companies with a high potential for disruption, capital efficient business models and a clear exit path. The fund will actively support portfolio companies through its team of experienced General and Venture Partners, a partnership with Cipactil and Enertech for human capital support and with Global Sustainable Future for debt financing of early commercial pilots, and by leveraging an extensive network of co-investors and strategic partners in the sector.
- Target fund size is \$50M.

FUND: Genoa Ventures - Seed - Series A, Biology and Technology

ABOUT: At the convergence of biology & technology lies enormous opportunity to accelerate the pace of innovation and transform industries. Genoa Ventures identifies these opportunities early and focuses our investments and expertise to empower the next great category-defying companies. Genoa pursues significant ownership via a concentrated early-stage (Seed, A) investing strategy.

å

å

4

- Genoa Ventures Fund II will build upon and scale our firm's success in Fund I (\$30M, 2018 vintage, 0.5X DPI).
- For over a decade, Genoa Ventures' Founder and Managing Director Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation and technology-fueled solutions. Jenny's investing experience includes roles at FPrime Capital (fka Fidelity Biosciences), Anterra Capital, and the Bill & Melinda Gates Foundation.

FUND: TBD

ABOUT:

*IPI is not an investment advisory service and is not a registered investment advisor or broker/dealer and has performed no due diligence and does not endorse any investment services, strategies, managers or investments listed on the IPI Deal Flow Platform including, IPI Co/Direct Investment, the IPI Deal Sheet, Managerlink, the Alternative Fund Manager Event or at any other IPI event, meeting or call. You should perform your own extensive due diligence.

Institute for Private Investors • P.O. Box 7022 • New York, NY • 10008 • www.instituteforprivateinvestors.com • www.memberlink.net • www.managerlink.net